Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Other Operating Expenses (2016 - 2020)

VYNE Therapeutics (VYNE) has disclosed Other Operating Expenses for 7 consecutive years, with $1000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Other Operating Expenses changed N/A year-over-year to $1000.0, compared with a TTM value of $1000.0 through Jun 2024, changed N/A, and an annual FY2020 reading of $139.1 million, changed N/A over the prior year.
  • Other Operating Expenses was $1000.0 for Q3 2023 at VYNE Therapeutics, down from $4.5 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $139.1 million in Q2 2020 and bottomed at -$37.6 million in Q1 2020.
  • Average Other Operating Expenses over 4 years is $8.8 million, with a median of -$450000.0 recorded in 2019.
  • The sharpest move saw Other Operating Expenses skyrocketed 15535.18% in 2020, then plummeted 92.06% in 2021.
  • Year by year, Other Operating Expenses stood at -$20.1 million in 2019, then soared by 792.83% to $139.1 million in 2020, then crashed by 96.76% to $4.5 million in 2021, then plummeted by 99.98% to $1000.0 in 2023.
  • Business Quant data shows Other Operating Expenses for VYNE at $1000.0 in Q3 2023, $4.5 million in Q4 2021, and $31.8 million in Q3 2021.